Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients

Journal of Infectious Diseases

Volumn 175, Issue 5, 1997, Pages 1087-1092

  Erice, Alejo ^a   Gil Roda, Cristina ^b   Pérez, José Luis ^c   Balfour Jr , Henry H ^e   Sannerud, Kim J ^e   Hanson, Michelle N ^e   Boivin, Guy ^d   Chou, Sunwen ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d LAVAL UNIVERSITY   (Canada)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; PRIORITY JOURNAL;

EID: 0030960868     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516446     Document Type: Article

References (25)

1. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986;67:1162-7.
2. Peterson PK, Balfour HH Jr, Marker SC, Fryd DS, Howard RJ, Simmons RL. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 1980;59:283-300.
3. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:585-94.
4. Balfour HH Jr. Management of cytomegalovirus disease with antiviral drugs. Rev Infect Dis 1990;12:S849-60.
5. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-96.
6. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-4.
7. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human Cytomegalovirus strains resistant to ganciclovir. J Virol 1994;68:4427-31.
8. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992;66:7146-52.
9. Sullivan V, Biron KK, Talarico C. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993;37:19-25.
10. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
11. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious CMV infection. J Infect Dis 1991;163:716-9.
12. Knox KK, Drobysky WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 1991;337:1292-3.
13. Drobyski WR, Knox KK, Carrigan DR, Ash RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 1991;52:155-7.
14. Chou S, Erice A, Jordan C, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576-83.
15. Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother 1995;39:1204-5.
16. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
17. Wolf DG, Lee DJ, Spector SA. Detection of human Cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother 1995;39:2552-4.
18. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-5.
19. Wolf DG, Smith IL, Lee DJ, Freeman WR, Flores-Aguilar M, Spector SA. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995;95:257-63.
20. Baldanti F, Silini E, Sarasini A, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol 1995;69:796-800.
21. Smith IL, Shinkai M, Freeman WR, Spector SA. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J Infect Dis 1996;173:1481-4.
22. Boivin G, Chou S, Quirk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996;173:523-8.
23. Crumpacker C, ed. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J Acquir Immune Defic Syndr 1996;12(suppl 1):S1-22.
24. Chou S. Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens. J Infect Dis 1990;162:738-42.
25. Erice A, Jordan CJ, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987;257:3082-7.